早期宫颈癌根治性子宫切除术范围与生存的关联:宫颈癌监测(SCCAN)协作研究亚组分析
这项国际多中心回顾性研究纳入1257例国际妇产科联盟2009分期IB1和IIA1期宫颈癌患者,比较保留神经与非保留神经根治性子宫切除术的5年无病生存和总生存。非保留神经组5年无病生存率93.8%,保留神经组90.1%(P=.047);多因素分析中非保留神经与更好的无病生存独立相关(HR 0.50)。肿瘤≤20 mm时两组无病生存无显著差异,21–40 mm时非保留神经组更优。
要点
- 肿瘤≤20 mm时,更根治性子宫切除术未显示生存差异。
- 肿瘤21–40 mm时,更根治性子宫切除术与改善的5年无病生存相关。
- 非保留神经根治性子宫切除术与更好的5年无病生存相关(HR 0.50)。
核心结论
- 肿瘤≤20 mm时,更根治性子宫切除术未发现生存差异。
- 肿瘤21–40 mm时,更根治性子宫切除术与改善的5年无病生存相关。
- 根据根治程度未观察到复发模式的差异。
- 倾向评分匹配分析后,非保留神经根治性子宫切除术与更好的5年无病生存相关。
研究设计与样本
- 国际多中心回顾性研究,来自宫颈癌监测(SCCAN)协作队列。
- 纳入2007年1月至2016年12月期间接受开腹B/C1/C2型根治性子宫切除术(Querleu-Morrow分类)、未行新辅助化疗、最终组织学淋巴结阴性且手术切缘自由的国际妇产科联盟2009分期IB1和IIA1期患者。
- 共纳入1257例患者,其中883例(70.2%)接受保留神经根治性子宫切除术,374例(29.8%)接受非保留神经根治性子宫切除术。
- 进行描述性统计和生存分析,按病理肿瘤直径分层,并进行倾向评分匹配分析以平衡保留神经与非保留神经根治性子宫切除术患者的基线特征。
主要发现
- 保留神经组与非保留神经组辅助治疗使用率分别为27.3% vs 28.6%(P=.63)。
- 保留神经组 vs 非保留神经组5年无病生存率分别为90.1%(95%CI 87.9-92.2) vs 93.8%(95%CI 91.1-96.5)(P=.047)。
- 全队列多因素分析中,非保留神经根治性子宫切除术与更好的无病生存独立相关(HR 0.50;95%CI 0.31-0.81;P=.004)。
- 保留神经组 vs 非保留神经组5年总生存率分别为95.7%(95%CI 94.1-97.2) vs 96.5%(95%CI 94.3-98.7)(P=.78)。
- 肿瘤直径≤20 mm时,保留神经组 vs 非保留神经组5年无病生存率分别为94.7% vs 96.2%(P=.22);肿瘤21–40 mm时,非保留神经组 vs 保留神经组5年无病生存率分别为90.3% vs 83.1%(P=.016),该亚组辅助治疗率无显著差异(P=.47),倾向评分匹配分析后得到证实。
关键数值与推荐
- 肿瘤≤20 mm:保留神经组5年无病生存率94.7% vs 非保留神经组96.2%(P=.22)。
- 肿瘤21–40 mm:非保留神经组5年无病生存率90.3% vs 保留神经组83.1%(P=.016)。
- 全队列多因素分析:非保留神经根治性子宫切除术 vs 保留神经,HR 0.50(95%CI 0.31-0.81;P=.004)。
- 倾向评分匹配人群中,复发模式无差异(P=.70)。
临床怎么用
- 对于肿瘤≤20 mm患者,更根治性子宫切除术未显示生存获益。
- 对于肿瘤21–40 mm患者,更根治性子宫切除术与改善的5年无病生存相关。
- 非保留神经根治性子宫切除术与更好的5年无病生存相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: International guidelines recommend tailoring the radicality of hysterectomy according to the known preoperative tumor characteristics in patients with early-stage cervical cancer. OBJECTIVE: This study aimed to assess whether increased radicality had an effect on 5-year disease-free survival in patients with early-stage cervical cancer undergoing radical hysterectomy. The secondary aims were 5-year overall survival and pattern of recurrence. STUDY DESIGN: This was an international, multicenter, retrospective study from the Surveillance in Cervical CANcer (SCCAN) collaborative cohort. Patients with the International Federation of Gynecology and Obstetrics 2009 stage IB1 and IIA1 who underwent open type B/C1/C2 radical hysterectomy according to Querleu-Morrow classification between January 2007 and December 2016, who did not undergo neoadjuvant chemotherapy and who had negative lymph nodes and free surgical margins at final histology, were included. Descriptive statistics and survival analyses were performed. Patients were stratified according to pathologic tumor diameter. Propensity score match analysis was performed to balance baseline characteristics in patients undergoing nerve-sparing and non-nerve-sparing radical hysterectomy. RESULTS: A total of 1257 patients were included. Of note, 883 patients (70.2%) underwent nerve-sparing radical hysterectomy, and 374 patients (29.8%) underwent non-nerve-sparing radical hysterectomy. Baseline differences between the study groups were found for tumor stage and diameter (higher use of non-nerve-sparing radical hysterectomy for tumors >2 cm or with vaginal involvement; P<.0001). The use of adjuvant therapy in patients undergoing nerve-sparing and non-nerve-sparing radical hysterectomy was 27.3% vs 28.6%, respectively (P=.63). Five-year disease-free survival in patients undergoing nerve-sparing vs non-nerve-sparing radical hysterectomy was 90.1% (95% confidence interval, 87.9-92.2) vs 93.8% (95% confidence interval, 91.1-96.5), respectively (P=.047). Non-nerve-sparing radical hysterectomy was independently associated with better disease-free survival at multivariable analysis performed on the entire cohort (hazard ratio, 0.50; 95% confidence interval, 0.31-0.81; P=.004). Furthermore, 5-year overall survival in patients undergoing nerve-sparing vs non-nerve-sparing radical hysterectomy was 95.7% (95% confidence interval, 94.1-97.2) vs non-nerve-sparing 96.5% (95% confidence interval, 94.3-98.7), respectively (P=.78). In patients with a tumor diameter ≤20 mm, 5-year disease-free survival was 94.7% in nerve-sparing radical hysterectomy vs 96.2% in non-nerve-sparing radical hysterectomy (P=.22). In patients with tumors between 21 and 40 mm, 5-year disease-free survival was 90.3% in non-nerve-sparing radical hysterectomy vs 83.1% in nerve-sparing radical hysterectomy (P=.016) (no significant difference in the rate of adjuvant treatment in this subgroup, P=.47). This was confirmed after propensity match score analysis (balancing the 2 study groups). The pattern of recurrence in the propensity-matched population did not demonstrate any difference (P=.70). CONCLUSION: For tumors ≤20 mm, no survival difference was found with more radical hysterectomy. For tumors between 21 and 40 mm, a more radical hysterectomy was associated with improved 5-year disease-free survival. No difference in the pattern of recurrence according to the extent of radicality was observed. Non-nerve-sparing radical hysterectomy was associated with better 5-year disease-free survival than nerve-sparing radical hysterectomy after propensity score match analysis.
引用
- Bizzarri N, Querleu D, Dostálek L, et al. Survival associated with extent of radical hysterectomy in early-stage cervical cancer: a subanalysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study. Am J Obstet Gynecol. 2023. PMID: 37336255. doi:10.1016/j.ajog.2023.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。